1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CCCGHS-NCI-T98-0085, NCI-T98-0085, NCI-99-C-0051B, T98-0085, NCT00019682
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 19 to 90
Sponsor: Other
Protocol IDs: SuMo-Sec-01, PEI 0899/01, IRB 07/03, NCT00108875
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: LUC 05-003, NCT00365937
|
|
4.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-99-C-0158, NCI-T99-0078, T99-0078, NCT00019942
|
|
5.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12095B, NCT00203892
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-06-C-0069, 7676, NCI-7676, NCI-P6703, NCT00304057
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: NHLBI
Protocol IDs: NHLBI-07-H-0159, 07-H-0159, NCT00499772
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: NHLBI
Protocol IDs: 070091, 07-H-0091, NCT00433745
|
|
9.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-08-C-0162, 08-C-0162, NCI-P07309, NCT00706992
|
|
10.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-09-C-0051, 09-C-0051, NCI-P08428, NCT00814684
|
|
11.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UPCC-11102, NCT00079157
|
|
12.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: PPMC-IRB-02-99, NCI-6361, 6361, NCT00091143
|
|
13.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD 2001-003, NCT00112242
|
|
14.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: NHLBI
Protocol IDs: 060062, 06-H-0062, NCT00270452
|
|
15.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BB-IND 12605, NCT00437502
|
|
16.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2006-001, MSKCC IRB# 07-152, NCT00616941
|
|
17.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 20 to 80
Sponsor: Other
Protocol IDs: AUGIS-001, NCT00624182
|
|
18.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 20 to 80
Sponsor: Other
Protocol IDs: TPR07-079, NCT00632333
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BB-IND 12605B, NCT00674791
|
|
20.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NYU 05-409, NCT00821652
|
|
21.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 20 to 80
Sponsor: Other
Protocol IDs: 20-27, NCT00845611
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: FVT-L0901, NCT00874588
|
|
23.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RPCI-I-127008, I 127008, NCT00887796
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 05-140, 1R01CA112198-01, NCT00819806
|
|
25.
|
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Status: Active
Age: 18 to 85
Sponsor: NCI
Protocol IDs: UVACC-MEL-38, UVACC-14499, UVACC-HIC-8380
|
